Biochemical markers of autoimmune diseases of the nervous system

Current Pharmaceutical Design

Volumn 18, Issue 29, 2012, Pages 4556-4563

  Tumani, Hayrettin ^a   Brettschneider, Johannes ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Biochemical markers; Cerebrospinal fluid; Guillain barr ; Limbic encephalitis; Multiple sclerosis; Myasthenia; Neuromyelitis optica; Neuromyotonia; Stiff person syndrome; Syndrome

Indexed keywords

AMPHIPHYSIN; AQUAPORIN 4; AQUAPORIN 4 ANTIBODY; AUTOANTIBODY; BIOCHEMICAL MARKER; CHEMOKINE RECEPTOR CXCR5; CHOLINERGIC RECEPTOR; CONTACTIN; CONTACTIN 2 ASSOCIATED PROTEIN; CXCL13 CHEMOKINE; G PROTEIN COUPLED RECEPTOR 30; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE DECARBOXYLASE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 17 RECEPTOR; LEUCINE RICH GLIOMA INACTIVATED 1 PROTEIN; MUSCLE SPECIFIC RECEPTOR TYROSINE KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; NEUROFILAMENT PROTEIN; POTASSIUM CHANNEL; PROTEIN S100B; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; ASSAY; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; DIFFERENTIAL DIAGNOSIS; EATON LAMBERT SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROIMMUNOPRECIPITATION ASSAY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOFLUORESCENCE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; MYOKYMIA; NONHUMAN; OPSOCLONUS MYOCLONUS SYNDROME; PARANEOPLASTIC NEUROPATHY; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RADIOIMMUNOPRECIPITATION; STIFF MAN SYNDROME;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; BIOLOGICAL MARKERS; HUMANS; PROGNOSIS;

EID: 84866363555     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802502143     Document Type: Article

References (110)

1. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004; 127: 1463-1478.
2. Blennow K, Wallin A, Hager O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand 1993; 88: 221-223.
3. Frohman EM, Filippi M, Stuve O, et al. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol 2005; 62: 1345-1356.
4. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
5. Lucchinetti CF, Bruck W, Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 2004; 56: 308.
6. Hemmer B, Cepok S, Nessler S, Sommer N. Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol 2002; 15: 227-231.
7. Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006; 59: 880-892.
8. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet Neurol 2008; 7: 852-858.
9. Aloisi F, Columba-Cabezas S, Franciotta D, et al. Lymphoid chemokines in chronic neuroinflammation. J Neuroimmunol 2008; 198: 106-112.
10. Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204: 2899-2912.
11. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005; 62: 865-870.
12. Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005; 128: 1667-1676.
13. Olsson JE, Link H. Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions. Arch Neurol 1973; 28: 392-399.
14. Villar LM, Masjuan J, Gonzalez-Porque P, et al. Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology 2002; 58: 824-826.
15. Graber JJ, Dhib-Jalbut S. Biomarkers of disease activity in multiple sclerosis. J Neurol Sci 2011; 305: 1-10.
16. Berger T, Reindl M. Biomarkers in multiple sclerosis: role of antibodies. Dis Markers 2006; 22: 207-212.
17. Zhou D, Srivastava R, Nessler S, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 19057-19062.
18. Dale RC, Brilot F, Banwell B. Pediatric central nervous system inflammatory demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol 2009; 22: 233-420.
19. Selter RC, Brilot F, Grummel V, et al. Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology 2010; 74: 1711-1715.
20. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349: 139-145.
21. Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007; 356: 371-378.
22. Menge T, Lalive PH, von Budingen HC, Cree B, Hauser SL, Genain CP. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol 2005; 116: 453-459.
23. Lolli F, Mulinacci B, Carotenuto A, et al. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. Proc Natl Acad Sci U S A 2005; 102: 10273-10278.
24. Schwarz M, Spector L, Gortler M, et al. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsingremitting multiple sclerosis. J Neurol Sci 2006; 244: 59-68.
25. Brettschneider J, Jaskowski TD, Tumani H, et al. Serum anti- GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J Neuroimmunol 2009; 217: 95-101.
26. Hecker M, Paap BK, Goertsches RH, et al. Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis. PloS One 2011; 6: e29648.
27. Tintore M, Rovira A, Rio J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008; 70: 1079-1083.
28. Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998; 4: 111-117.
29. Tumani H, Tourtellotte WW, Peter JB, Felgenhauer K. Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. The Optic Neuritis Study Group. J Neurol Sci 1998; 155: 44-49.
30. Jarius S, Franciotta D, Bergamaschi R, et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 2008; 79: 1134-1136.
31. Brettschneider J, Tumani H, Kiechle U, et al. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PloS One 2009; 4: e7638.
32. Sindic CJ, Monteyne P, Laterre EC. The intrathecal synthesis of virus-specific oligoclonal IgG in multiple sclerosis. J Neuroimmunol 1994; 54: 75-80.
33. Corcione A, Casazza S, Ferretti E, et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci USA 2004; 101: 11064-11669.
34. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298: 2199-2202.
35. Robinson Agramonte MA, Reiber H, Dorta Contreras AJ, Hernandez Diaz E. Intrathecal oligoclonal and polyspecific immune response in multiple sclerosis. Rev Neurol 2001; 33: 809-811.
36. Nelson PJ, Krensky AM. Chemokines, chemokine receptors, and allograft rejection. Immunity 2001; 14: 377-386.
37. Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009; 73: 2003-2010.
38. Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006; 129: 200-211.
39. Brettschneider J, Czerwoniak A, Senel M, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PloS One 2010; 5: e11986.
40. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011; 17: 335-343.
41. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-1114.
42. de Seze J, Stojkovic T, Ferriby D, et al. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 2002; 197: 57-61.
43. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol.6: 383-392.
44. Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 2008; 15: 99-105.
45. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
46. Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68: 1076-1077.
47. Marignier R, De Seze J, Vukusic S, et al. NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler 2008; 14: 440-445.
48. Takahashi T, Fujihara K, Nakashima I, et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 2006; 210: 307-313.
49. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130: 1235-1243.
50. Waters P, Jarius S, Littleton E, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008; 65: 913-919.
51. Paul F, Jarius S, Aktas O, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007; 4: e133.
52. Apiwattanakul M, McKeon A, Fryer JP, Hinson SR, Pittock SJ, Lennon VA. AQP4-IgG immunoprecipitation assay optimization. Clin Chem 2009; 55: 592-594.
53. Hayakawa S, Mori M, Okuta A, et al. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J neuroimmunology 2008; 196: 181-187.
54. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008; 131: 3072-3080.
55. Matsuoka T, Matsushita T, Kawano Y, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007; 130: 1206-1223.
56. Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 2009; 80: 575-577.
57. Miyazawa I, Nakashima I, Petzold A, Fujihara K, Sato S, Itoyama Y. High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology 2007; 68: 865-867.
58. Meinck HM. Stiff man syndrome. CNS Drugs 2001; 15: 515-526.
59. Whiteley AM, Swash M, Urich H. Progressive encephalomyelitis with rigidity. Brain 1976; 99: 27-42.
60. Warich-Kirches M, Von Bossanyi P, Treuheit T, et al. Stiff-man syndrome: possible autoimmune etiology targeted against GABAergic cells. Clin Neuropathol 1997; 16: 214-219.
61. Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322: 1555-1560.
62. Dinkel K, Meinck HM, Jury KM, Karges W, Richter W. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol 1998; 44: 194-201.
63. de Camilli P, Thomas A, Cofiell R, et al. The synaptic vesicleassociated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 1993; 178: 2219-2223.
64. Butler MH, Hayashi A, Ohkoshi N, et al. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 2000; 26: 307-312.
65. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-1098.
66. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000; 123 (Pt 7): 1481-1494.
67. Vedeler CA, Storstein A. Autoimmune limbic encephalitis. Acta Neurol Scand Suppl 2009; 189: 68-7.
68. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124: 1138-1148.
69. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapyresponsive form of limbic encephalitis. Brain 2004; 127: 701-712.
70. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9: 776-785.
71. Vincent A, Irani SR. Caspr2 antibodies in patients with thymomas. J thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2010; 5: S277-S280.
72. Knudsen A, Bredholt G, Storstein A, et al. Antibodies to CRMP3-4 associated with limbic encephalitis and thymoma. Clin Exp Immunol 2007; 149: 16-22.
73. Tuzun E, Rossi JE, Karner SF, Centurion AF, Dalmau J. Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis. J Neuroimmunol 2007; 186: 177-180.
74. Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126: 1409-1418.
75. Graus F, Dalmau J. Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol 2007; 20: 732-737.
76. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-1140.
77. Blaes F, Fuhlhuber V, Korfei M, et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 2005; 58: 313-317.
78. Phillips LH, 2nd. The epidemiology of myasthenia gravis. Ann N Y Acad Sci 2003; 998: 407-412.
79. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008; 37: 141-149.
80. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8: 475-490.
81. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26: 1054-1059.
82. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985; 48: 1246-1252.
83. Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 2007; 36: 651-658.
84. Cikes N, Momoi MY, Williams CL, et al. Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. Mayo Clin Proc 1988; 63: 474-481.
85. Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 2005; 62: 442-446.
86. Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology 2001; 57: 1579-1582.
87. Suzuki S, Satoh T, Yasuoka H, et al. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol 2005; 170: 141-149.
88. Vincent A, McConville J, Farrugia ME, Newsom-Davis J. Seronegative myasthenia gravis. Semin Neurol 2004; 24: 125-133.
89. McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004; 55: 580-584.
90. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008; 131: 1940-1952.
91. Farrugia ME, Vincent A. Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol 2010; 23: 489-495.
92. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111 (Pt 3): 577-596.
93. Vincent A. Autoimmune disorders of the neuromuscular junction. Neurol India 2008; 56: 305-313.
94. Graus F, Vincent A, Pozo-Rosich P, et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 2005; 165: 166-171.
95. Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008; 70: 924-928.
96. Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 2002; 125: 1887-1895.
97. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol 2008; 7: 939-950.
98. Lang B, Vincent A. Autoimmune disorders of the neuromuscular junction. Curr Opin Pharmacol 2009; 9: 336-340.
99. Willison HJ. The immunobiology of Guillain-Barre syndromes. J Peripher Nerv Syst 2005; 10: 94-112.
100. Willison HJ. Ganglioside complexes: new autoantibody targets in Guillain-Barre syndromes. Nat Clin Pract Neurol 2005; 1: 2-3.
101. Kusunoki S, Kaida K, Ueda M. Antibodies against gangliosides and ganglioside complexes in Guillain-Barre syndrome: new aspects of research. Biochim Biophys Acta 2008; 1780: 441-444.
102. Kanzaki M, Kaida K, Ueda M, et al. Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain-Barre syndromes. J Neurol Neurosurg Psychiatry 2008; 79: 1148-1152.
103. Jacobs BC, Koga M, van Rijs W, et al. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barre syndrome. J Neuroimmunol 2008; 194: 181-190.
104. Guillain G, Lereboullet J, et al. [Not Available.]. Bull Mem Soc Med Hop Paris 1947; 63: 773-775.
105. van der Meche FG, van Doorn PA, Meulstee J, Jennekens FG. Diagnostic and classification criteria for the Guillain-Barre syndrome. Eur Neurol 2001; 45: 133-139.
106. Brettschneider J, Petzold A, Sussmuth S, Tumani H. Cerebrospinal fluid biomarkers in Guillain-Barre syndrome--where do we stand? J Neurol 2009; 256: 3-12.
107. Jin K, Takeda A, Shiga Y, et al. CSF tau protein: a new prognostic marker for Guillain-Barre syndrome. Neurology 2006; 67: 1470-1472.
108. Petzold A, Hinds N, Murray NM, et al. CSF neurofilament levels: a potential prognostic marker in Guillain-Barre syndrome. Neurology 2006; 67: 1071-1073.
109. Sussmuth SD, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 2001; 300: 95-98.
110. Mokuno K, Kiyosawa K, Sugimura K, et al. Prognostic value of cerebrospinal fluid neuron-specific enolase and S-100b protein in Guillain-Barre syndrome. Acta Neurol Scand 1994; 89: 27-30.